Jenkins’ Drug Divisions
FDA Office of New Drugs Director John Jenkins has 17 drug divisions that report to him (See "FDA’s Outlook on the Drug Approval Drought," in this issue). Here are the divisions and current directors:
Norman Stockbridge, MD
Director, Division of Cardiovascular and Renal Products <p>
<p>Phone: 301-796-2240 </p>
<p>Email: norman.stockbridge@fda.hhs.gov </p>
<name>Russell Katz, MD <p>
<title>Director, Division of Neurology Products <p>
<p>Phone: 301-796-2250 </p>
<p>Email: russell.katz@fda.hhs.gov </p>
<name>Thomas Laughren, MD <p>
<title>Director, Division of Psychiatry Products <p>
<p>Phone: 301-796-2260 </p>
<p>Email: thomas.laughren@fda.hhs.gov </p>
<name>Robert Rappaport, MD <p>
<title>Director, Division of Anesthesia, Analgesia and Rheumatology Products <p>
<p>Phone: 301-796-2280 </p>
<p>Email: robert.rappaport@fda.hhs.gov </p>
<name>Mary Parks, MD <p>
<title>Director, Divsion of Metabolism and Endocrinology Products <p>
<p>Phone: 301-796-2290 </p>
<p>Email: mary.parks@fda.hhs.gov </p>
<name>Badrul Chowdhury, MD <p>
<title>Director, Division of Pulmonary and Allergy Products <p>
<p>Phone: 301-796-2300 </p>
<p>Email: badrul.chowdhury@fda.hhs.gov </p>
<name>Daniel Shames, MD <p>
<title>Acting Director, Division of Gastroenterology Products <p>
<p>Phone: 301-796-2120 </p>
<p>Email: daniel.shames@fda.hhs.gov </p>
<name>Susan Walker, MD <p>
<title>Director, Division of Dermatology and Dental Products <p>
<p>Phone: 301-796-2110 </p>
<p>Email: susan.walker@fda.hhs.gov </p>
<name>Scott Monroe, MD <p>
<title>Acting Director, Division of Reproductive and Urologic Products <p>
<p>Phone: 301-796-2130 </p>
<p>Email: scott.monroe@fda.hhs.gov </p>
<name>Janice Soreth, MD <p>
<title>Director, Division of Anti-Infective and Ophthalmology Products <p>
<p>Phone: 301-796-1400 </p>
<p>Email: janice.soreth@fda.hhs.gov </p>
<name>Debra Bimkrant, MD <p>
<title>Director, Division of Antiviral Products <p>
<p>Phone: 301-796-1500 </p>
<p>Email: debra.bimkrant@fda.hhs.gov </p>
<name>Renata Albrecht, MD <p>
<title>Director, Division of Special Pathogens and Transplant Products <p>
<p>Phone: 301-796-1600 </p>
<p>Email: renata.albrecht@fda.hhs.gov </p>
<name>Robert Justice, MD <p>
<title>Director, Division of Drug Oncology Products <p>
<p>Phone: 301-796-2330 </p>
<p>Email: robert.justice@fda.hhs.gov </p>
<name>Rafel Dwaine Rieves, MD <p>
<title>Acting Director, Division of Medical Imaging and Hematology Products <p>
<p>Phone: 301-796-2050 </p>
<p>Email: rafel.rieves@fda.hhs.gov </p>
<name>Patricia Keegan, MD <p>
<title>Title: Director, Division of Biologic Oncology Products <p>
<p>Phone: 301-796-2320 </p>
<p>Email: patricia.keegan@fda.hhs.gov </p>
<name>Scott Furness, PhD <p>
<title>Director, Division of Nonprescription Regulation Development <p>
<p>Phone: 301-796-2090 </p>
<p>Email: michael.furness@fda.hhs.gov </p>
<name>Andrea Leonard-Segal, MD <p>
<title>Title: Director, Division of Nonprescription Clinical Evaluation <p>
<p>Phone: 301-796-2080 </p>
<p>Email: andrea.leonardsegal@fda.hhs.gov
